S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in

Varian Medical Systems (NYSE:VAR) Stock Rating Lowered by UBS Group

Tuesday, February 23, 2021 | MarketBeat

Varian Medical Systems (NYSE:VAR) was downgraded by research analysts at UBS Group from a "buy" rating to an "in-line" rating in a report released on Tuesday, 24/7 WallStreet reports.

Several other research analysts have also recently commented on VAR. Barrington Research cut Varian Medical Systems from an "outperform" rating to an "underperform" rating in a research report on Wednesday, October 28th. Robert W. Baird lowered shares of Varian Medical Systems from an "outperform" rating to a "neutral" rating and set a $178.00 price target on the stock. in a research report on Wednesday, October 28th. Finally, Jefferies Financial Group downgraded Varian Medical Systems from a "buy" rating to a "hold" rating and set a $178.00 price target for the company. in a research note on Monday, December 7th. Three analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. The stock presently has an average rating of "Hold" and a consensus price target of $145.55.

Shares of NYSE VAR opened at $176.03 on Tuesday. Varian Medical Systems has a 52-week low of $89.62 and a 52-week high of $176.50. The stock has a market cap of $16.17 billion, a P/E ratio of 60.08 and a beta of 1.06. The firm has a 50 day moving average price of $175.81 and a 200 day moving average price of $173.93.

Varian Medical Systems (NYSE:VAR) last posted its quarterly earnings data on Monday, January 25th. The medical equipment provider reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. The business had revenue of $778.80 million for the quarter, compared to analysts' expectations of $832.97 million. Varian Medical Systems had a net margin of 8.50% and a return on equity of 18.45%. The firm's revenue was down 6.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.16 EPS. On average, analysts forecast that Varian Medical Systems will post 5.2 EPS for the current year.

In other news, CEO Dow R. Wilson sold 157,515 shares of the stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $174.35, for a total value of $27,462,740.25. Following the sale, the chief executive officer now directly owns 203,945 shares of the company's stock, valued at $35,557,810.75. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Magnus Momsen sold 4,473 shares of the firm's stock in a transaction that occurred on Thursday, December 10th. The shares were sold at an average price of $174.95, for a total transaction of $782,551.35. Following the completion of the transaction, the chief accounting officer now owns 4,549 shares of the company's stock, valued at $795,847.55. The disclosure for this sale can be found here. Insiders have sold 177,897 shares of company stock worth $31,020,935 over the last quarter. 0.78% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in VAR. Pentwater Capital Management LP bought a new position in Varian Medical Systems in the 3rd quarter worth about $137,600,000. Hartford Investment Management Co. increased its holdings in shares of Varian Medical Systems by 9.6% in the 4th quarter. Hartford Investment Management Co. now owns 10,410 shares of the medical equipment provider's stock worth $1,822,000 after buying an additional 908 shares during the last quarter. Canton Hathaway LLC purchased a new stake in shares of Varian Medical Systems during the 3rd quarter valued at $94,000. Nissay Asset Management Corp Japan ADV raised its position in shares of Varian Medical Systems by 2.6% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 10,516 shares of the medical equipment provider's stock valued at $1,840,000 after buying an additional 265 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Varian Medical Systems during the 3rd quarter worth $164,000. 86.96% of the stock is currently owned by hedge funds and other institutional investors.

About Varian Medical Systems

Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment.

See Also: What is a dead cat bounce?

Analyst Recommendations for Varian Medical Systems (NYSE:VAR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Stocks That Will Help You Forget About the Fed

Normally when the Federal Reserve (i.e. the Fed) makes an announcement, the market reacts predictably. That’s due, in large part, to the nature of what the Fed normally announces. Will interest rates go up, down, or remain unchanged? And for their part, the markets have a pretty good idea what the Fed will do before they do it.

But the Fed’s announcement of August 26 was a little different. They talked briefly about interest rates (they’re staying really low for a long time). But they were more concerned about inflation. Well, the Fed is always concerned about inflation, but this time they really mean it. Basic economics says that low-interest rates should spur inflation.

However, the market has been defying conventional wisdom and the Fed is not getting the inflation they want. So the Fed has basically said that they’re letting inflation go rogue. If it goes above their target 2% rate, so be it. The Fed is done trying to hit a target. At first, the markets cheered the news. Not only was the Fed not taking away the punch bowl, but they were also going to keep the low rate liquidity going for a long time!

But after a little while to digest things, investors are realizing they have to be grown-ups about this. And now investors are considering how to rebalance their portfolios for the remainder of 2020.

I don’t know about them, but if I were you I would target companies that have a high free cash flow (FCF). Whether it’s your personal finances or in evaluating a stock, cash flow is your friend.

When a corporation has high FCF, they have more strong growth in good markets and more flexibility during when the economy is weaker.

As institutional investors come back into the market, it’s time for you to reposition your portfolio for whatever comes next.

View the "7 Stocks That Will Help You Forget About the Fed".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.